Recursion Pharmaceuticals (RXRX) PT Raised to $15 at KeyBanc
Tweet
Share
E-mailGet Alerts RXRX Hot Sheet
Price: $3.31 --0%
Rating Summary:
4 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 8 | New: 7
Rating Summary:
4 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 8 | New: 7
Join SI Premium – FREE
KeyBanc analyst Scott Schoenhaus raised the price target on Recursion Pharmaceuticals (NASDAQ: RXRX) to $15.00 (from $12.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Veritone (VERI) PT Lowered to $5 at Needham
- Yeti Holdings Inc. (YETI) PT Raised to $48 at BofA Securities
- Globant S.A. (GLOB) PT Lowered to $45 at Needham
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
